Couto Maria Eduarda, Oliveira Isabel, Domingues Nelson, Viterbo Luísa, Martins Ângelo, Moreira Ilídia, Espírito-Santo Ana, Chacim Sérgio, Moreira Cláudia, Pereira Dulcineia, Henrique Rui, Mariz José
Department of Onco-hematology, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
Department of Pathology and Cancer Biology and Epigenetics Group - Research Centre (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
Indian J Hematol Blood Transfus. 2021 Jul;37(3):492-496. doi: 10.1007/s12288-020-01391-9. Epub 2021 Jan 2.
Gastric diffuse large B cell lymphoma (DLBCL) represents the majority of all gastric lymphomas. We report a series of gastric DLBCL diagnosed and treated in a single center, between 2010 and 2018 (included). We retrospectively analyzed the population demographic features, treatment outcomes and survival. One-hundred-and-one patients were studied, 50.5% males and median age of 64 years [23-94]. Lugano staging was I in 16.8%, II1 in 20.8%, II2 in 10.9%, IIE in 13.9% and IV in 34.7% of cases. Twenty percent had infection. R-CHOP- therapy was used as first line in 96.9% of the patients. A complete response was achieved in 80% after first line therapy. At 3-years of follow-up (FU), 54% were in complete remission. The mean FU time was 73.6 months. Median overall survival and median progression free survival were not reached. We identified seven factors with negative impact in survival: age above 65 years-old ( < 0.01), ECOG 2-3 ( < 0.01), B symptoms ( = 0.001), bulky disease ( = 0.003), IPI 3-4 ( = 0.001), more than 3 treatment lines ( < 0.01), absence of response to first line treatment ( < 0.01). This study demonstrates that gastric DLBCL is a potentially curable disease with R-CHOP- therapy, entailing long term survival and comparing well with other published series.
胃弥漫性大B细胞淋巴瘤（DLBCL）占所有胃淋巴瘤的大多数。我们报告了2010年至2018年（含）在单一中心诊断和治疗的一系列胃DLBCL病例。我们回顾性分析了患者的人口统计学特征、治疗结果和生存情况。共研究了101例患者，其中男性占50.5%，中位年龄为64岁（23 - 94岁）。根据卢加诺分期，I期占16.8%，II1期占20.8%，II2期占10.9%，IIE期占13.9%，IV期占34.7%。20%的患者合并感染。96.9%的患者一线治疗采用R-CHOP方案。一线治疗后80%的患者达到完全缓解。随访3年时，54%的患者处于完全缓解状态。平均随访时间为73.6个月。总生存中位数和无进展生存中位数均未达到。我们确定了对生存有负面影响的七个因素：年龄大于65岁（<0.01）、美国东部肿瘤协作组（ECOG）体能状态评分为2 - 3分（<0.01）、B症状（=0.001）、大包块病变（=0.003）、国际预后指数（IPI）为3 - 4分（=0.001）、接受超过3线治疗（<0.01）、对一线治疗无反应（<0.01）。本研究表明，胃DLBCL采用R-CHOP方案治疗有潜在治愈可能，可实现长期生存，与其他已发表系列研究结果相当。
